NovaBay Pharmaceuticals (NBY) Company Overview

NovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that its Special Meeting of Stockholders held on November 22, 2024 has been adjourned until December 18, 2024 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold of favorabl.

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces that the largest institutional advisory firm, Institutional Shareholder Services (ISS), has recommended that NovaBay stockholders vote in favor of all of the Company's proxy proposals, specifically to authorize and approve the sale of its eyecare business (the “Asset Sale Proposal”) and approve the voluntary liquidation and dissolution of the Company (the “Dissolution.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NovaBay Pharmaceuticals, Inc.'s (NYSE American: NBY) Avenova brand and business to Physician Recommended Nutriceuticals, LLC for $9.5 million in cash is fair to NovaBay shareholders. Halper Sadeh encourages NovaBay shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or zhalper.

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will be offering special promotions and discounts on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month. National Dry Eye Awareness Month is intended to recognize the importance of eye health to overall health, and to educate the public about dry eye. The Sjögren's Foundation and its partners first asked Con.

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) announces that the NYSE American LLC (“NYSE American”) has accepted the Company's plan to regain compliance with NYSE American's continued listing standards. “I'm pleased to report on our forward momentum. By divesting an unprofitable business segment earlier this year, we're now able to focus solely on our core competency in eyecare,” said Justin Hall, CEO of NovaBay. “Unshackled by past bu.

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. the “Company”) (NYSE American: NBY) announces that a quorum was reached and that all proposals in the Company's Definitive Proxy Statement filed on April 18, 2024 with the Securities and Exchange Commission (the “SEC”) were approved by stockholders at its 2024 Annual Meeting of Stockholders held on May 28, 2024. Among the proposals, stockholders approved a reverse stock split and authorized the Company's Board of Directors to d.

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) will release financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. An investment community conference call will follow at 4:30 p.m. Eastern time on the same day. Participants can pre-register for the call by clicking the provided link.

NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Jody Cain - LHA, IR Justin Hall - CEO and General Counsel Tommy Law - Interim CFO Conference Call Participants Destiny Buch - Ladenburg Thalmann Operator Welcome to the NovaBay Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.